Dave Fornell, DAIC Editor

Dave Fornell, Editor DAIC

Blog | Dave Fornell, DAIC Editor | January 30, 2017

DAIC’s Website Broke 1 Million Pageviews; Two Key TCT Takeaways

DAIC has worked hard to bring useful technology news and resources to our readers. While we conduct reader surveys and speak to readers at site visits and conferences, one of the clearest views we have of reader interests is based on what they are reading on our website, e-newsletters and digital editions. We have responded to these analytics in what we publish and how we cover new cardiovascular technology. The result has been a big increase in our online readership over the past year. For the first time, DAIC’s website broke 1 million pageviews in November 2016. We wanted to thank our readers for helping us reach this milestone. 

See a list of the “Most Popular Cardiology Articles of 2016 From DAIC.”

See the list of “Top Cardiology Videos on DAIC in 2016.”

 

Two Key Takeaways at TCT 2016

After decompressing from the interventional information overload at the annual Transcatheter Cardiovascular Therapeutics (TCT) conference in November, I felt there were two big technology takeaways requiring an in-depth review.  These included the EXCEL Trial and the results of three studies that compared bioresorbable polymer metallic drug-eluting stents (DES) to the current standard durable polymer metallic DES. 

The EXCEL Trial was the biggest news at TCT.16. It compared the use of the Abbott Xience V DES to coronary artery bypass graft (CABG) surgery in patients with left main disease. The result of this large randomized trial was that both have equal outcomes. You can read the article with more detail at  "Stents Have Equal Outcomes to Bypass Surgery in EXCEL Trial."

Durable drug-carrier polymers on DES have been implicated as the cause of late-stent thrombosis, which has led to long-duration use of dual antiplatelet therapy (DAPT). The introduction of bioresorbable polymers was expected to eliminate late events and the need for long-term DAPT. However, results from three trials of bioresorbable polymer DES showed equal outcomes and no apparent benefit. Read more detail and here Boston Scientific's response to the data in the article "Bioresorbable Polymers on Metallic Stents Show No Superiority to Durable Polymer Stents."

 

New DAIC Editorial Board Members

DAIC recently added two new Editorial Board members who are experts in cutting-edge interventional and structural heart technologies. The first is Azeem Latib, M.D., an interventional cardiologist at Università Vita-Salute San Raffaele Milano, Milan, Italy. He is a regular speaker at  TCT and other conferences. His research interests include new transcatheter heart valve repair and replacement technologies and bioresorbable stents. Read his recent article on the Cardioband annuloplasty device, "Transcatheter Annuloplasty For Repair Versus Replacement in Functional Mitral Regurgitation."

Our second new board member is Torsten Vahl, M.D., director of experimental and translational research and assistant professor of medicine at Columbia University Medical Center, The Center for Interventional Vascular Therapy. He also is a regular speaker at TCT and is involved in bleeding-edge research and trials for new structural heart interventions. Watch a video interview with Vahl at TCT 2016, "Transcatheter Valve Technology Advancements at TCT 2016."
 

Related Content

Edwards Lifesciences Pascal Tricuspid Valve Transcatheter Repair System Approved in Europe
News | Heart Valve Technology | May 18, 2020
May 18, 2020 — The Edwards Lifesciences Corp.
Key TAVR Takeaways From ACC 2020
Feature | Heart Valve Technology | April 20, 2020 | Dave Fornell, Editor
Some U.S.
Abbott announced its TriClip Transcatheter Tricuspid Valve Repair (TTVR) System has received European CE mark clearance as a non-surgical treatment for people with a tricuspid valve regurgitation (TR). 
Feature | Heart Valve Technology | April 09, 2020
April 9, 2020 — Abbott announced its TriClip Transcatheter Tricuspid Valve Repair (TTVR) System has received European
The Edwards Lifesciences Cardioband for tricuspid valve regurgitation. #COVID19 #coronavirus

The Edwards Lifesciences Cardioband for tricuspid valve regurgitation is one of the device trials being paused for the duration of the COVID-19 outbreak.

News | Heart Valve Technology | March 30, 2020
March 30, 2020 — Edwards Lifesciences Corp.
Conclusions from the TAVR vs surgery trial for aortic valve replacement in the U.K. presented by William D. Toff, M.D. at ACC 20. #ACC20 #ACC2020 #TAVR #TAVR

Conclusions from the real world TAVR vs. surgery trial for aortic valve replacement outcomes in the U.K., presented by William D. Toff, M.D. at ACC 20. 

News | Heart Valve Technology | March 30, 2020
March 30, 2020 — Patients in the United Kingdom (U.K.) who underwent transcatheter aortic valve replacement (TAVR) di
PARTNER 3 trial shows positive results for Sapien 3 in low-risk surgical patients. #ACC20 #ACC2020 #Sapien3 #TAVR
Feature | Heart Valve Technology | March 30, 2020
March 30, 2020 — Low-risk patients undergoing transcatheter aortic valve repair (TAVR) at two years did just as well
News | Heart Valve Technology | March 29, 2020
March 29, 2020 — Worse than expected outcomes were found for survival and quality of life among patients undergoing t
Patients with bicuspid, or two-leaflet, aortic valves who undergo transcatheter aortic valve replacement (TAVR) procedures had a high rate of success and low risk of death or disabling stroke at 30 days, according to new data presented at the American College of Cardiology (ACC) 2020 Scientific Session. #ACC20 #ACC2020
Feature | Heart Valve Technology | March 29, 2020 | Dave Fornell, Editor
March 29, 2020 — Patients with bicuspid, or two-leaflet, aortic valves who undergo transcatheter aortic valve replace
The heart team at St. James University Hospital Dublin was the first to perform a human implant of the CroiValve Duo Tricuspid Coaptation Valve technology for tricuspid repair.  

The heart team at St. James University Hospital Dublin was the first to perform a human implant of the CroiValve Duo Tricuspid Coaptation Valve technology for tricuspid repair.  

News | Heart Valve Technology | March 25, 2020
 
A 3-D reconstruction of a cardiac CT scan showing an implanted Medtronic CoreValve TAVR device. Imagine courtesy of TeraRecon. #TAVR #TAVI

A 3-D reconstruction of a cardiac CT scan showing an implanted Medtronic CoreValve TAVR device. Image courtesy of TeraRecon

Feature | Heart Valve Technology | February 24, 2020 | Dave Fornell, Editor
In August 2019, the U.S.